Department of Surgery, NorthShore University Health System, Evanston, IL; Department of Surgery, Wyckoff Heights Medical Center, Brooklyn, NY.
Department of Surgery, Harlem Hospital Center, New York, NY.
J Am Coll Surg. 2020 Jan;230(1):136-144. doi: 10.1016/j.jamcollsurg.2019.09.021. Epub 2019 Oct 28.
Thyroid lobectomy (TL) has been proposed as definitive surgical treatment for papillary thyroid cancers (PTC) up to 4 cm. This study evaluates the use and appropriateness of TL for T1b and T2 PTC.
The National Cancer Database was interrogated for adult patients having TL for T1b-T2 PTC between 2004 and 2014. Patients who should have undergone total thyroidectomy (TT) instead of lobectomy based on high-risk tumor features were identified. The 2 groups were compared for clinical and demographic characteristics, and overall survival.
Of 8,083 patients undergoing lobectomy, 1,552 patients had high-risk features and should have undergone TT. These included 194 with cN1, 571 with pN1, 307 with lymphovascular invasion (LVI), 645 with extra thyroidal extension (ETE), 567 with positive margins, 42 with poorly differentiated PTC, and 25 with M1 disease. At 10 years of follow-up, 92.4% of appropriate lobectomy (aTL) patients were alive compared with 88.5% of inappropriate lobectomy (iTL) patients (p < 0.001). On univariate and multivariable Cox survival analysis, age greater than 45 years, male sex, comorbidities, government or no insurance, low income, and tumor size >2 cm were associated with poorer survival (all p < 0.05). Thyroid lobectomy patients with high-risk features had significantly higher mortality on unadjusted (hazard ratio [HR] 1.98, 95% CI 1.52 to 2.59, p < 0.001) and adjusted survival analysis (HR 1.97, 95% CI 1.51 to 2.58, p < 0.001). Total thyroidectomy with radioiodine treatment had improved overall survival in comparison to iTL (HR 0.65, 95% CI 0.51 to 0.83, p < 0.001).
A substantial number of patients (19.2%) with tumor size >1 cm and high-risk features undergo thyroid lobectomy for PTC. Exclusion of high-risk features is important when adopting lobectomy as the definitive surgical therapy for T1b and T2 PTC because they have a potential adverse effect on long-term survival.
甲状腺叶切除术(TL)已被提议作为直径达 4 厘米的甲状腺乳头状癌(PTC)的确定性手术治疗方法。本研究评估了 TL 在 T1b 和 T2 PTC 中的应用和适宜性。
国家癌症数据库在 2004 年至 2014 年间,检索了接受 TL 治疗 T1b-T2 PTC 的成年患者。确定了基于高危肿瘤特征本应接受全甲状腺切除术(TT)而非叶切除术的患者。比较了这两组患者的临床和人口统计学特征以及总生存率。
在 8083 例接受叶切除术的患者中,有 1552 例患者存在高危特征,应接受 TT。其中 194 例患者存在 cN1,571 例患者存在 pN1,307 例患者存在血管淋巴管侵犯(LVI),645 例患者存在甲状腺外侵犯(ETE),567 例患者存在阳性切缘,42 例患者存在低分化 PTC,25 例患者存在 M1 疾病。在 10 年的随访中,92.4%的合适叶切除术(aTL)患者存活,而不合适叶切除术(iTL)患者的存活率为 88.5%(p<0.001)。在单变量和多变量 Cox 生存分析中,年龄大于 45 岁、男性、合并症、政府或无保险、低收入和肿瘤大小>2cm 与生存率较差相关(均 p<0.05)。甲状腺叶切除术后高危特征的患者,在未调整(危险比[HR]1.98,95%CI 1.52 至 2.59,p<0.001)和调整生存分析(HR 1.97,95%CI 1.51 至 2.58,p<0.001)中死亡率均显著升高。与 iTL 相比,全甲状腺切除术联合放射性碘治疗可显著提高总生存率(HR 0.65,95%CI 0.51 至 0.83,p<0.001)。
相当数量(19.2%)的肿瘤大小>1cm 且存在高危特征的患者因 PTC 而行甲状腺叶切除术。在将叶切除术作为 T1b 和 T2 PTC 的确定性手术治疗方法时,排除高危特征非常重要,因为它们对长期生存有潜在的不利影响。